AlphAIAlphAI — Financial news for AI agents
investing.com$KYMR

Kymera earnings on deck with atopic dermatitis drug in focus

Kymera Therapeutics (KYMR) is set to report Q3 earnings, with investors focusing on the year-end trial readout for its atopic dermatitis drug KT-621. Analysts expect a loss of $1.27 per share on $3.1M revenue. The stock has 22 Buy ratings, with a mean target of $139.83. Key focus areas include trial timing, cash runway, and Phase 3 planning. KT-621 aims to match injectable biologics' efficacy while offering oral therapy advantages.

Original reporting
investing.com
Published Oct 28, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 3:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KYMR
Neutral
high confidence
Mentioned
$KYMR
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KYMRNeutralMed
01

Why it matters

The upcoming earnings release and trial readout are the first public disclosures of timing and expectations, making this a primary news event.

02

Market read

Earnings preview and trial expectations create a near‑term trading catalyst for KYMR.

03

What to watch

Cash runway concerns and the need for additional financing may limit upside even with positive trial data.

Relevance 7/10Novelty 7/10Timing: pre‑market Thursday

Background

Kymera Therapeutics (NASDAQ: KYMR) is a biotech developing oral degraders for Type 2 inflammatory diseases.

Company-level read

Ticker impact

$KYMRNeutralHigh confidence
Context

Kymera Therapeutics is set to report Q3 earnings and investors are focused on the upcoming BROADEN2 Phase 2b trial readout for its KT-621 drug.

Expected impact

potential upside if trial data is positive, downside pressure if results miss expectations

Evidence & confidence

The article provides new guidance on earnings loss, revenue expectations, and a key clinical trial timeline that traders will price in.

Market effects

Sector

Positive trial data could boost the broader biotech sector focused on oral protein degraders.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond biotech investors.

Counterpoint

What could challenge this read

If the trial fails, the stock could see a sharp sell‑off despite the earnings preview hype.

Key entities

  • company
    Kymera Therapeutics Inc.

    Biotech firm developing KT-621 oral degrader.

  • analyst
    Morgan Stanley

    Raised price target to $146.

  • analyst
    Citigroup

    Lifted price target to $150.

Read at source← All news

StoryKymera Therapeutics posts $132 million Q3 loss, zero revenue and unveils strong Phase 1 data for IRF5 degrader KT‑579

Also covered by

3 outlets

Related articles

$KYMRMed

Kymera (KYMR) Q3 2026 Earnings Call Transcript

Kymera (KYMR) reported Q3 2026 earnings, highlighting progress in its pipeline, including Phase IIb data for KT-621 in atopic dermatitis (AD) expected by year-end. The BROADEN 2 study's placebo-controlled portion is complete, with 98% of eligible patients enrolling in the open-label extension. The company also discussed market research indicating a demand for safe, effective oral treatments for AD.

finance.yahoo.com
$KYMRMed

Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics reported Q3 results, highlighting 98% inhibition of TLR7/8-stimulated interferon-beta levels and positive phase I data for KT-579. The company plans a phase Ib lupus study (LUMORA) in early 2027. KT-621 is expected to show atopic dermatitis efficacy comparable to dupilumab. Q3 R&D expenses were $128.5M, with cash position of $1.6B providing runway into 2029.

finance.yahoo.com
$KYMRMedAI 8/10

Kymera Q3 2026 slides: IRF5 degrader shows 90%+ target engagement

Kymera Therapeutics (KYMR) reported Q3 2026 results, missing earnings but showing 90%+ target engagement for its IRF5 degrader KT-579. The stock rose 3.46% premarket. The company reported a net loss of $132M, up from $82.2M YoY, with R&D expenses increasing 73%. Kymera has $1.6B in cash, providing a runway into 2029. KT-579 showed promising Phase 1 data, with significant biomarker reductions and a favorable safety profile.

investing.com
$KYMRHigh

Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary

Kymera Therapeutics reported 3Q 2026 revenue of $0, down from $2.8M a year earlier, and a net loss of $132M, or $(1.32) per share, compared to a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter. The company's collaboration revenue for the nine months increased to $99.4M, driven by partnerships with Gilead and Sanofi. Research and development spending rose 49%, primarily due to expanded program work and personnel investments.

tradingview.com
$KYMRHighAI 8/10

Kymera reports phase 1 data for KT-579, plans lupus trial

Kymera Therapeutics (KYMR) reported phase 1 trial results for KT-579, showing significant IRF5 degradation and biomarker reductions. The company plans a phase 1b lupus trial in 2027. Q3 2026 net loss was $132.0M, up from $82.2M in 2025, with R&D expenses increasing. Cash reserves are $1.6B, expected to last into 2029. Updates on other clinical trials were also provided.

investing.com